Cargando…
PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
Autores principales: | Bouchakor Moussa, Y., Taoussi, S., Oukid, S., Lamraoui, F., Rekab, N., Benlabiod, K. M., Brahimi, H., Abad, M. T., Bradai, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429072/ http://dx.doi.org/10.1097/01.HS9.0000850440.38789.88 |
Ejemplares similares
-
PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023) -
PB1905: FEASIBILITY OF TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE: RESULTS FROM A SERIES OF 19 PATIENTS
por: KACHA, F., et al.
Publicado: (2022) -
PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Mahtat, E. M., et al.
Publicado: (2022) -
PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
por: Bektaş, M., et al.
Publicado: (2022) -
PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)